Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:12 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Erythropoietin in Premature Infants to Prevent Encephalopathy
NCT02550054 · Children's Hospital of Fudan University · PHASE2 · terminated · last registry update 2023-12-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.” | – | Registry record, Children's Hospital of Fudan University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EPOR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-12-13Results posted on the registry: Syros Pharmaceuticals, Tamibarotene + Azacitidine (NCT02807558)
- 2024-12-09Also stopped (terminated): Hospital Son Espases, Paricalcitol + Epoetin beta (NCT02876211)
- 2024-12-06Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., SAL-0951 tablets + rHuEPO injection (NCT06720025)
- 2024-10-30Results posted on the registry: NICHD Neonatal Research Network, Darbepoetin + Placebo (NCT03169881)
- 2024-10-04Also stopped (terminated): Belfast Health and Social Care Trust, ARA290 (NCT06626971)
- 2024-08-23Results posted on the registry: Universitaire Ziekenhuizen KU Leuven, Antithrombin-III + Infliximab (NCT02251041)
- 2024-08-01Results posted on the registry: Kyntra Bio, Roxadustat + Placebo (NCT03263091)
- 2024-08-01Also stopped (terminated): Kyntra Bio, Roxadustat + Placebo (NCT03263091)
- 2024-07-25Phase 3 first posted: USRC Kidney Research, Vadadustat + Erythropoiesis Stimulating Agent (NCT06520826)
- 2024-06-26Results posted on the registry: Celgene, Luspatercept + Epoetin alfa (NCT03682536)
- 2024-06-26Also stopped (terminated): Institut du Cancer de Montpellier - Val d'Aurelle, epoetin beta + systemic chemotherapy (NCT00875004)
- 2024-06-20Phase 3 first posted: Genexine, Inc., Efepoetin Alfa + Darbepoetin Alfa (NCT06466785)
- 2024-04-22Results posted on the registry: AstraZeneca, Roxadustat + rHuEPO (NCT04655027)
- 2024-04-08Phase 3 first posted: Megalabs, Experimental: Epoetin alfa Megalabs® Erythropoietin injectable in intravenous administration. + Active comparator: European Union licenced epoetin alfa (NCT06352138)
- 2024-04-02Also stopped (terminated): Ontario Clinical Oncology Group (OCOG), Epoetin Alfa (NCT00310232)
- 2024-03-27Also stopped (terminated): GlaxoSmithKline, Daprodustat + Darbepoetin alfa (NCT03446612)
- 2023-11-18Phase 3 first posted: Ain Shams University, erythropoietin + Triamcinolone acetonide (NCT06135259)
- 2023-08-24Results posted on the registry: Celgene, Luspatercept (NCT03194542)
- 2023-07-25Results posted on the registry: GlaxoSmithKline, Daprodustat + rhEPO (NCT03457701)
- 2023-07-25Results posted on the registry: University of New Mexico, Darbepoetin Alfa + Normal Saline (NCT03071861)
- 2023-07-18Phase 3 first posted: Bristol-Myers Squibb, Luspatercept + Epoetin Alfa (NCT05949684)
- 2023-06-18Phase 3 first posted: The First Affiliated Hospital of Soochow University, Decitabine + Granulocyte Colony-Stimulating Factor (NCT05907499)
- 2023-03-15Phase 3 first posted: Hallym University Medical Center, Ferric Derisomaltose Injection + Darbepoetin Alfa Injection (NCT05768997)
- 2023-02-28Phase 3 first posted: Asociación para Evitar la Ceguera en México, Recombinant human erythropoietin 4,000 UI and 2,000 UI + Methylprednisolone succinate 500 mg (NCT05748561)
- 2023-01-30Results posted on the registry: University of California, San Francisco, Normal saline placebo + Erythropoietin (NCT02811263)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision